Samantha Jaglowski, MD, MPH, on Next Steps Regarding Tisagenlecleucel for Patients with DLBCL

Article

The associate professor at The Ohio State University Comprehensive Cancer Center explained the goals for the future of the CAR T-cell therapy data in patients with DLBCL.

Samantha Jaglowski, MD, MPH, associate professor at The Ohio State University Comprehensive Cancer Center, discussed next steps regarding her analysis of the CAR T-cell therapy tisagenlecleucel (Kymriah) in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) using the Center for International Blood and Marrow Transplant Research (CIBMTR) database at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition, held December 7-10, in Orlando, Florida.

Transcription:
Really the next step is, this is really very germinal, this is the first readout of the tisagen data submitted to the CIBMTR, so the next steps are really going to be to accrue more patients. There’s a goal of collecting 2,500 tisagen patients and currently there are a bit over 100 that we’re reporting on, so the goal is for this to be a really large suppository of data and we’re not there yet. We will be there, but you know it’ll be important to continue to follow this with time.

Related Videos
Janice Chen, PhD, the cofounder and chief technology officer of Mammoth Biosciences
Sekar Kethiresan, MD, on Following up VERVE-101 With Next-Generation Editing Therapies
Maria Escolar, MD, the chief medical officer of Forge Biologics
Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies
John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Erika Fullwood Augustine, MD, MS, the associate chief science officer of the Kennedy Krieger Institute
Maria Escolar, MD, the chief medical officer of Forge Biologics
Casey Maguire, PhD, associate professor of neurology and associate investigator of neurology, Harvard Medical School
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
© 2024 MJH Life Sciences

All rights reserved.